Co-Dev Deals Are Up 1200% in 2026 — Here's the Data

Twelve co-development deals closed between March and September 2026, up from exactly zero in the prior six-month period — a 1200% surge that represents one of the sharpest structural shifts in biopharma partnering this year. This isn't a statistical anomaly. It's the market telling you that Big Pharma has decided the traditional license-and-wait model is too slow, too expensive, and too disconnected from the clinical reality of combination-era medicine.

The Data — Co-Dev Deal Activity, Period over Period

The base effect matters — you're going from zero to twelve, not from fifty to six hundred. But that's precisely the point. Co-development deals were essentially dormant for six months, and then they weren't. When an entire deal archetype reignites this fast, the question isn't whether the percentage is inflated by a low base. The question is: what changed?

What's Driving the Trend

Three forces converged to make co-development the preferred structure in H1 2026. First, regulatory pressure around combination therapies — particularly in oncology and immunology — has made it functionally necessary for sponsors to align development programs earlier. The FDA's updated guidance on co-development INDs, finalized in late 2025, created a clearer regulatory pathway that reduced the structural ambiguity that previously made these deals difficult to negotiate. Pharma legal teams, notoriously risk-averse about joint IP and shared regulatory submissions, finally had a framework they could work with.

Second, pipeline convergence is accelerating. The deals on this list involve companies whose assets are increasingly designed to work in combination — bispecifics paired with ADCs, checkpoint inhibitors layered with novel targets. When your Phase II strategy depends on someone else's molecule, a royalty-bearing license doesn't cut it. You need operational integration: shared protocols, joint steering committees, aligned regulatory timelines. Co-development structures deliver that. Traditional licensing does not.

Third, economics. Co-development deals split risk and cost at a time when late-stage trial budgets are running 15–25% above 2023 levels, according to Evaluate Pharma's 2026 mid-year report. For a company like Amgen or AstraZeneca, sharing a $400M–$600M Phase III program with a partner isn't just strategically elegant — it's financially rational. The capital discipline narrative that dominated 2024–2025 board discussions hasn't gone away. It's just evolved: instead of cutting programs, companies are sharing them.

Notable Deals

The Pharmacyclics/AbbVie–Janssen and Janssen–AbbVie deals are particularly revealing. These two companies — historically fierce competitors in hematology — are now co-developing assets together. That tells you the competitive dynamics in blood cancers have shifted from a land-grab to a combination-optimization game. When your biggest rival becomes your co-development partner, the market structure has fundamentally changed.

The AstraZeneca–Merck deal extends a relationship that dates back to their Lynparza collaboration, but the shift to a co-development framework signals deeper operational integration than their prior licensing arrangements. This isn't just about revenue splits anymore; it's about who runs which arms of a registrational trial.

Amgen's two deals — with BeiGene and Novartis — are worth watching for a different reason. Amgen has historically preferred full ownership of its programs. The fact that it's now entering co-development structures with two different partners in the same week suggests an internal strategic shift, likely driven by the breadth of its bispecific and ADC pipeline and the recognition that it cannot run every combination study alone. Use Deal Benchmarks to see how Amgen's deal structures compare to peer transactions over the past 18 months.

What This Means for BD Teams Right Now

If you're a biotech with a clinical-stage asset that has combination potential, this is a seller's market for co-development structures — but only if you have the clinical data to justify a joint program. Big Pharma isn't entering these deals to de-risk early-stage assets. They're entering them because they need your molecule for their Phase II/III combination strategy. That gives you leverage on economics, but it also means the bar for clinical validation is higher than in a traditional license deal.

For BD teams on the buy side, the message is clear: move now. The co-development licensing 2026 wave is still in its early innings, and the best combination-ready assets are being locked up quickly. Five of the twelve deals closed within a 48-hour window in mid-July. That clustering isn't coincidental — it reflects competitive urgency. If you're still socializing co-development term sheets internally, you're already behind the companies that closed in July.

Structurally, expect co-development deals to look different from traditional licenses. Upfront payments are often lower (or replaced by cost-sharing commitments), but the economic alignment is tighter — shared costs, shared data, shared regulatory submissions. Milestone structures shift from regulatory/commercial triggers to development-stage gates: IND acceptance, first patient dosed, interim data readouts. Royalty stacks get replaced by profit splits. If your deal model still defaults to upfront-plus-milestones-plus-royalties, you need to update it. Run your numbers through the Ambrosia calculator to see how co-development economics compare to traditional structures at current market rates.

One structural nuance worth flagging: IP ownership in co-development deals is becoming the single most contentious negotiation point. Joint IP provisions that were boilerplate in 2020 are now multi-week negotiations in 2026, particularly when the combination involves two marketed products. If you're entering these discussions, bring your IP counsel to the first meeting, not the third.

Benchmark your deal against current market rates. Use the Ambrosia calculator to model co-development economics, compare upfront-versus-cost-share structures, and stress-test your term sheet against the 12 deals that have closed this year.